
manigrover
Novice
Sep 16, 2013, 5:43 AM
Post #21 of 42
(19105 views)
|
Re: [BillKSmith] Request to change Perl code according to desired output
[In reply to]
|
Can't Post
|
|
I was able to convert all tab spaces to blank space Here is example rom my data file after conversion TTDS00002 UniProt ID P11229 TTDS00002 Name Muscarinic acetylcholine receptor M1 TTDS00002 Type of target Successful target TTDS00002 Synonyms M1 receptor TTDS00002 Disease Alzheimer's disease TTDS00002 Disease Bronchospasm (histamine induced) TTDS00002 Disease Cognitive deficits TTDS00002 Disease Schizophrenia TTDS00002 Function The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. TTDS00002 Sequence MNTSAPPAVSPNITVLAPGKGPWQVAFIGITTGLLSLATVTGNLLVLISFKVNTELKTVNNYFLLSLACADLIIGTFSMNLYTTYLLMGHWALGTLACDLWLALDYVASNASVMNLLLISFDRYFSVTRPLSYRAKRTPRRAALMIGLAWLVSFVLWAPAILFWQYLVGERTVLAGQCYIQFLSQPIITFGTAMAAFYLPVTVMCTLYWRIYRETENRARELAALQGSETPGKGGGSSSSSERSQPGAEGSPETPPGRCCRCCRAPRLLQAYSWKEEEEEDEGSMESLTSSEGEEPGSEVVIKMPMVDPEAQAPTKQPPRSSPNTVKRPTKKGRDRAGKGQKPRGKEQLAKRKTFSLVKEKKAARTLSAILLAFILTWTPYNIMVLVSTFCKDCVPETLWELGYWLCYVNSTINPMCYALCNKAFRDTFRLLLLCRWDKRRWRKIPKRPGSVHRTPSRQC TTDS00002 BioChemical Class G-protein coupled receptor (rhodopsin family) TTDS00002 Pathway Calcium signaling pathway TTDS00002 Pathway Neuroactive ligand-receptor interaction TTDS00002 Pathway Regulation of actin cytoskeleton TTDS00002 Related US Patent 6,288,068 TTDS00002 Related US Patent 6,294,554 TTDS00002 Related US Patent 6,627,645 TTDS00002 Drug(s) Pirenzepine DAP000492 Peptic ulcer disease Approved TTDS00002 Drug(s) Glycopyrrolate DAP001116 Anesthetic Approved TTDS00002 Drug(s) Clidinium DAP001117 Abdominal/stomach pain Approved TTDS00002 Drug(s) Dicyclomine DAP001118 Irritable bowel syndrome Approved TTDS00002 Drug(s) Ethopropazine DAP001119 Parkinson's disease Approved TTDS00002 Drug(s) Cycrimine DAP001120 Parkinson's disease Approved TTDS00002 Drug(s) Benztropine DAP001121 Parkinson's disease Approved TTDS00002 Drug(s) Trihexyphenidyl DAP001122 Parkinson's disease Approved TTDS00002 Drug(s) Propantheline DAP001123 Excessive sweating (hyperhidrosis) Approved TTDS00002 Drug(s) Oxyphenonium DAP001124 Spasm Approved TTDS00002 Drug(s) Biperiden DAP001125 Parkinson's disease Approved TTDS00002 Antagonist Pirenzepine DAP000492 TTDS00002 Antagonist Glycopyrrolate DAP001116 TTDS00002 Antagonist Clidinium DAP001117 TTDS00002 Antagonist Dicyclomine DAP001118 TTDS00002 Antagonist Ethopropazine DAP001119 TTDS00002 Antagonist Benztropine DAP001121 TTDS00002 Antagonist Trihexyphenidyl DAP001122 TTDS00002 Antagonist Propantheline DAP001123 TTDS00002 Antagonist Oxyphenonium DAP001124 TTDS00002 Antagonist Biperiden DAP001125 TTDS00002 Binder Cycrimine DAP001120 TTDS00002 Drug(s) Talsaclidine isomer DCL000268 Alzheimer's disease Discontinued TTDS00002 Drug(s) Sabcomeline hydrochloride DCL000279 Cardiovascular diseases Phase IIa TTDS00002 Drug(s) Talsaclidine fumarate DCL000303 Alzheimer's disease Discontinued TTDS00002 Drug(s) Xanomeline tartrate DCL000328 Alzheimer's disease Phase II TTDS00002 Drug(s) GSK573719 DCL000381 Chronic Obstructive Pulmonary Disease (COPD) Phase II TTDS00002 Drug(s) GSK961081 DCL000397 Chronic Obstructive Pulmonary Disease (COPD) Phase II completed TTDS00002 Drug(s) GSK1034702 DCL000402 Schizophrenia, Dementia Phase I completed TTDS00002 Drug(s) Darotropium DCL000514 COPD Suspended in Phase II in GSK 2009 Report TTDS00002 Drug(s) Darotropium + 642444 DCL000515 COPD Phase III TTDS00002 Drug(s) Revatropate DCL000957 Chronic obstructive pulmonary disease Discontinued in Phase I TTDS00002 Antagonist Revatropate DCL000957 TTDS00002 Agonist Talsaclidine isomer DCL000268 TTDS00002 Agonist Sabcomeline hydrochloride DCL000279 TTDS00002 Agonist Talsaclidine fumarate DCL000303 TTDS00002 Agonist Xanomeline tartrate DCL000328 TTDS00002 Agonist GSK573719 DCL000381 TTDS00002 Agonist GSK961081 DCL000397 TTDS00002 Agonist GSK1034702 DCL000402 TTDS00002 Agonist Darotropium DCL000514 TTDS00002 Agonist Darotropium + 642444 DCL000515 TTDS00002 Multitarget GSK961081 DCL000397 TTDS00002 Multitarget Revatropate DCL000957 TTDS00002 Agonist 77-LH-28-1 DNC000099 TTDS00002 Agonist AC-260584 DNC000137 TTDS00002 Agonist AC-42 DNC000138 TTDS00002 Agonist AF150(S) DNC000165 TTDS00002 Agonist AF267B DNC000166 TTDS00002 Agonist LY-593039 DNC000910 TTDS00002 Agonist NGX-267 DNC001012 TTDS00002 Agonist Sabcomeline DNC001264 TTDS00002 Agonist WAY-132983 DNC001510 TTDS00002 Inhibitor Arecoline DNC002508 TTDS00002 Inhibitor Acetic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester DNC003640 TTDS00002 Inhibitor Benzoic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester DNC003654 TTDS00002 Inhibitor Propionic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester DNC003659 TTDS00002 Inhibitor 3-Methyl-7-pyrrolidin-1-yl-hept-5-yn-2-one DNC004147 TTDS00002 Inhibitor 2-Methyl-6-pyrrolidin-1-yl-hex-4-ynal oxime DNC004159 TTDS00002 Inhibitor ISOCLOZAPINE DNC004166 TTDS00002 Inhibitor SB-202026 DNC004272 TTDS00002 Inhibitor HIMBACINE DNC004995 TTDS00002 Inhibitor RR(17)PZ DNC005944 TTDS00002 Inhibitor Bo(15)PZ DNC005945 TTDS00002 Inhibitor DIFLUOROBENZTROPINE DNC005986 TTDS00002 Inhibitor BI-1356 DNC007901 TTDS00002 Inhibitor FM1-10 DNC008187 TTDS00002 Inhibitor FM1-43 DNC008188 TTDS00002 Inhibitor A-987306 DNC008996 TTDS00002 Inhibitor GNF-PF-5618 DNC009476 TTDS00002 Inhibitor CREMASTRINE DNC009504 TTDS00002 Inhibitor 1,1-diphenyl-2-(3-tropanyl)ethanol DNC009866 TTDS00002 Inhibitor R-dimethindene DNC009877 TTDS00002 Inhibitor Tiotropium Bromide DNC009882 TTDS00002 Inhibitor XANOMELINE DNC011170 TTDS00002 Inhibitor 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DNC011171 TTDS00002 Inhibitor 1-Methyl-1-(4-pyrrolidin-1-yl-but-2-ynyl)-urea DNC011427 TTDS00002 Inhibitor ISOLOXAPINE DNC011498 TTDS00002 Inhibitor 1'-Benzyl-3-phenyl-[3,4']bipiperidinyl-2,6-dione DNC011500 TTDS00002 Inhibitor CARAMIPEN DNC011755 TTDS00002 Inhibitor FLUMEZAPINE DNC011857 TTDS00002 Inhibitor AMINOBENZTROPINE DNC011950 TTDS00002 Inhibitor 2-(4-Diethylamino-but-2-ynyl)-isoindole-1,3-dione DNC012005 TTDS00002 Inhibitor 3-Tetrazol-2-yl-1-aza-bicyclo[2.2.2]octane DNC012098 TTDS00002 Inhibitor SULFOARECOLINE DNC012122 TTDS00002 Inhibitor 6-Dimethylamino-2-methyl-hex-4-ynal oxime DNC012306 TTDS00002 Inhibitor 7-Pyrrolidin-1-yl-hept-5-yn-2-one DNC012322 TTDS00002 Inhibitor 7-Dimethylamino-3-methyl-hept-5-yn-2-one DNC012323 TTDS00002 Inhibitor 7-Pyrrolidin-1-yl-hept-5-yn-2-one oxime DNC012330 TTDS00002 Inhibitor 7-Dimethylamino-hept-5-yn-2-one DNC012350 TTDS00002 Inhibitor 7-Dimethylamino-hept-5-yn-2-one oxime DNC012351 TTDS00002 Inhibitor N-(4-Dimethylamino-but-2-ynyl)-N-methyl-acetamide DNC012363 TTDS00002 Inhibitor ACECLIDINE DNC012502 TTDS00002 Inhibitor N-methoxyquinuclidine-3-carboximidoyl fluoride DNC012588 TTDS00002 Inhibitor BRL-55473 DNC012594 TTDS00002 Inhibitor N-methoxyquinuclidine-3-carboximidoyl chloride DNC012616 TTDS00002 Inhibitor 2,8-Dimethyl-1-oxa-8-aza-spiro[4.5]decan-3-one DNC012765 TTDS00002 Inhibitor 3alpha-(bis-chloro-phenylmethoxy)tropane DNC013136 TTDS00002 Inhibitor 3-(3-benzylamino)-piperidin-2-one DNC013219 TTDS00002 Target Validation TTDS00002 TTDS00003 UniProt ID P08172 TTDS00003 Name Muscarinic acetylcholine receptor M2 TTDS00003 Type of target Successful target TTDS00003 Synonyms M2 receptor TTDS00003 Disease Alzheimer's disease TTDS00003 Disease Analgesics TTDS00003 Disease Autoimmune cardiomyopathy TTDS00003 Disease Bronchoconstriction (cold air-induced) TTDS00003 Disease Chronic obstructive pulmonary disease, unspecified TTDS00003 Disease Hypothermia TTDS00003 Disease Neurogenic bladder TTDS00003 Disease Pain, unspecified TTDS00003 Disease Tremor, unspecified TTDS00003 Function The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. TTDS00003 Sequence MNNSTNSSNNSLALTSPYKTFEVVFIVLVAGSLSLVTIIGNILVMVSIKVNRHLQTVNNYFLFSLACADLIIGVFSMNLYTLYTVIGYWPLGPVVCDLWLALDYVVSNASVMNLLIISFDRYFCVTKPLTYPVKRTTKMAGMMIAAAWVLSFILWAPAILFWQFIVGVRTVEDGECYIQFFSNAAVTFGTAIAAFYLPVIIMTVLYWHISRASKSRIKKDKKEPVANQDPVSPSLVQGRIVKPNNNNMPSSDDGLEHNKIQNGKAPRDPVTENCVQGEEKESSNDSTSVSAVASNMRDDEITQDENTVSTSLGHSKDENSKQTCIRIGTKTPKSDSCTPTNTTVEVVGSSGQNGDEKQNIVARKIVKMTKQPAKKKPPPSREKKVTRTILAILLAFIITWAPYNVMVLINTFCAPCIPNTVWTIGYWLCYINSTINPACYALCNATFKKTFKHLLMCHYKNIGATR TTDS00003 PDB Structure 1LUB TTDS00003 BioChemical Class G-protein coupled receptor (rhodopsin family) TTDS00003 Pathway Calcium signaling pathway TTDS00003 Pathway Neuroactive ligand-receptor interaction TTDS00003 Pathway Regulation of actin cytoskeleton TTDS00003 Related US Patent 6,288,068 TTDS00003 Related US Patent 6,294,554 TTDS00003 Related US Patent 6,498,168 TTDS00003 Related US Patent 6,500,822 TTDS00003 Related US Patent 6,627,644 TTDS00003 Related US Patent 6,635,658 TTDS00003 Related US Patent 6,645,958 TTDS00003 Related US Patent 6,667,301 TTDS00003 Drug(s) Scopolamine DAP000343 Nausea and Addiction Approved TTDS00003 Drug(s) Methylscopolamine DAP001126 Peptic ulcer disease Approved TTDS00003 Drug(s) Gallamine Triethiodide DAP001127 Stabilize muscle contractions Approved TTDS00003 Antagonist Scopolamine DAP000343 TTDS00003 Antagonist Methylscopolamine DAP001126 TTDS00003 Antagonist Gallamine Triethiodide DAP001127 TTDS00003 Antagonist (R)-4-[2-[3-(4-methoxy-benzoylamino)-benzyl]-piperidin-1-ylmethyl]piperidine-1-carboxylic acid amide (Ro-320-6206) DNC000011 TTDS00003 Antagonist AF-DX116 DNC000167 TTDS00003 Agonist CMI-1145 DNC000455 Let me know if it helps or I have to do something else
|